Framework can improve Alzheimer's treatment efficacy by tracking anti-Aβ therapy response

In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made in a laboratory to stimulate the immune…

Continue Reading

News Source: medicalxpress.com